SCHEMBL29601272

SCHEMBL29601272

CCOC(=O)C(Br)C(=O)c1ccccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.58
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 2/20 0.49
GAA P10253 2/20 0.49
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
PKM P14618 2/20 0.46
NPC1 O15118 2/20 0.46
MITF O75030 1/20 0.46
RAB9A P51151 1/20 0.46
LMNA P02545 2/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.43
NAPRT Q6XQN6 1/20 0.43
P4HTM Q9NXG6 1/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8190351 1.00 GSK3B (0.58) GSK3BKMT2ASMN1; SMN2MEN1GAA
Bromide SCHEMBL29938709 0.98 GSK3B (0.57) GSK3BKMT2ASMN1; SMN2MEN1GAA
Bromide SCHEMBL15993360 0.98 GSK3B (0.57) GSK3BKMT2ASMN1; SMN2MEN1GAA
SCHEMBL27196361 0.83 GSK3B (0.51) GSK3BKMT2ASMN1; SMN2MEN1GAA
SCHEMBL19782876 0.81 GSK3B (0.54) GSK3BKMT2ASMN1; SMN2MEN1GAA
SCHEMBL19782386 0.79 GSK3B (0.51) GSK3BKMT2ASMN1; SMN2MEN1GAA
SCHEMBL19782990 0.78 BRD4 (0.45) KMT2ASMN1; SMN2MEN1GAAALDH1A1
SCHEMBL19782864 0.78 GSK3B (0.57) GSK3BKMT2ASMN1; SMN2MEN1GAA
SCHEMBL29601629 0.78 GSK3B (0.66) GSK3BKMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL15993270 0.78 GSK3B (0.66) GSK3BKMT2ASMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
WO-2022087326-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-04-28 WO disclosed